CRISPR Therapeutics (CRSP) incurred a loss of 1.49pershareinthesecondquarterof2024,whichwaswiderthantheZacksConsensusEstimateofalossof1.37. In the year-ago period, the company had incurred a loss of 98 cents per share.The company’s total revenues, though negligible, were entirely from grant revenues, which were 0.5millioninthesecondquarter.ThereportedfiguresignificantlymissedtheZacksConsensusEstimateof8 million.In the year-ago quarter, the company generated collabora ...